1st vaccine to protect against respiratory syndrome in babies approved – Cities

Anvisa (National Health Surveillance Agency) approved, this Monday (1st), the first vaccine that protects babies against the respiratory syncytial virus, which causes respiratory tract infections, particularly bronchiolitis.

Named Abrysvo, the medicine is produced by the company Pfizer and should be applied to pregnant women during the third trimester of pregnancy. This means that, to protect children, the vaccine must be administered to mothers. The vaccine is not administered directly to babies.

Considered bivalent, as it is composed of two antigens from the RSV F surface protein, administration is intramuscular and the dosage schedule involves the application of a single dose.

In the note sent to the press, the agency explains that it had already authorized the registration of the Arexvy vaccine (GlaxoSmith Kline), also intended for the prevention of diseases caused by RSV, but with indications restricted to the population over the age of 60.

Its use was also authorized to prevent lower respiratory tract disease caused by RSV in individuals aged 60 or over, a population also considered at risk.

“Still, the totality of evidence presented to Anvisa was able to demonstrate that the benefits of the vaccine are greater than its risks. Its effectiveness, safety and quality were also proven in terms of Resolution RDC No. 55/2010, which deals with registration of biological products”, highlights the technical note.

Receive the main state news on your cell phone. Click here to access the Campo Grande News channel on WhatsApp and follow our social media.